An Open-Label, Multicenter, Non-Comparative, Phase II Study of Oral Topotecan in Combination With Bevacizumab for Second-Line Treatment in Subjects With Relapsed Small-Cell Lung Cancer (SCLC).
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2012
At a glance
- Drugs Bevacizumab; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 23 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Aug 2009 Planned end date (Feb 2010) added as reported by ClinicalTrials.gov.